ESTROGENS, CONJUGATED Estrogeni Coniuncti A

Total Page：16

File Type：pdf, Size：1020Kb

ESTROGENS, CONJUGATED Estrogeni Coniuncti A

Estrogens, conjugated EUROPEAN PHARMACOPOEIA 8.0 – impurities B, C, D, E, F, G: for each impurity, not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent); – unspecified impurities:foreachimpurity,notmorethan 0.1 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent); E. estra-1,3,5(10)-triene-3,16α,17α-triol (17-epi-estriol), – sum of impurities other than A: not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (1 per cent); – disregard limit: 0.05 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent). F. estra-1,3,5(10)-triene-3,16β,17β-triol (16-epi-estriol), Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C for 3 h. ASSAY Dissolve 25.0 mg in ethanol (96 per cent) R and dilute to 50.0mLwiththesamesolvent.Dilute10.0mLofthis solution to 50.0 mL with ethanol (96 per cent) R.Measurethe absorbance (2.2.25)attheabsorptionmaximumat281nm. G. estra-1,3,5(10)-triene-3,16β,17α-triol (16,17-epi-estriol), Calculate the content of C18H24O3 taking the specific absorbance to be 72.5. IMPURITIES Specified impurities: A, B, C, D, E, F, G. Other detectable impurities (the following substances would, H. 3,16α-dihydroxyestra-1,3,5(10)-trien-17-one, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use):H,I. I. 3-hydroxy-17-oxa-D-homoestra-1,3,5(10)-trien-17a-one. 01/2008:1512 ESTROGENS, CONJUGATED Estrogeni coniuncti A. estra-1,3,5(10),9(11)-tetraene-3,16α,17β-triol (9,11-didehydroestriol), B. 3-hydroxyestra-1,3,5(10)-trien-17-one (estrone), C18H21O5NaS + C18H19O5NaS Mr 372.4 + 370.4 DEFINITION Mixture of various conjugated forms of estrogens obtained from the urine of pregnant mares or by synthesis, dispersed in asuitablepowdereddiluent. The 2 principal components are 17-oxoestra-1,3,5(10)- trien-3-yl sodium sulfate (sodium estrone sulfate) and C. 3-methoxyestra-1,3,5(10)-triene-16α,17β-diol (estriol 17-oxoestra-1,3,5(10),7-tetraen-3-yl sodium sulfate (sodium 3-methyl ether), equilin sulfate). Concomitants are sodium 17α-estradiol sulfate, sodium 17α-dihydroequilin sulfate and sodium 17β-dihydroequilin sulfate. Content (percentages related to the labelled content): – sodium estrone sulfate: 52.5 per cent to 61.5 per cent; – sodium equilin sulfate: 22.5 per cent to 30.5 per cent; – sodium 17α-estradiol sulfate: 2.5 per cent to 9.5 per cent; – sodium 17α-dihydroequilin sulfate: 13.5 per cent to 19.5 per D. estradiol, cent; 2174 See the information section on general monographs (cover pages).

Copy Link

Recommended publications

United States July 2016 2 Table of Contents
Deuterium Labelled Compounds United States July 2016 2 Table of Contents International Distributors 3 Corporate Overview 4 General Information 5 Pricing and Payment 5 Quotations 5 Custom Synthesis 5 Shipping 5 Quality Control 6 Quotations 6 Custom Synthesis 6 Shipping 6 Quality Control 6 Chemical Abstract Service Numbers 6 Handling Hazardous Compounds 6 Our Products are Not Intended for Use in Humans 7 Limited Warranty 7 Packaging Information 7 Alphabetical Listings 8 Stock Clearance 236 Products by Category 242 n-Alkanes 243 α-Amino Acids, N-Acyl α-Amino Acids, N-t-BOC Protected α-Amino Acid 243 and N-FMOC Protected α-Amino Acids Buffers and Reagents for NMR Studies 245 Detergents 245 Environmental Standards 246 Fatty Acids and Fatty Acid Esters 249 Flavours and Fragrances 250 Gases 253 Medical Research Products 254 Nucleic Acid Bases and Nucleosides 255 Pesticides and Pesticide Metabolites 256 Pharmaceutical Standards 257 Polyaromatic Hydrocarbons (PAHs), Alkyl-PAHs, Amino-PAHs, 260 Hydroxy-PAHs and Nitro-PAHs Polychlorinated Biphenyls (PCBs) 260 Spin Labels 261 Steroids 261 3 International Distributors C Beijng Zhenxiang H EQ Laboratories GmbH Australia K Technology Company Graf-von-Seyssel-Str. 10 Rm. 15A01, Changyin Bld. 86199 Augsburg Austria H No. 88, YongDingLu Rd. Germany Beijing 100039 Tel.: (49) 821 71058246 Belgium J China Fax: (49) 821 71058247 Tel.: (86) 10-58896805 [email protected] China C Fax: (86) 10-58896158 www.eqlabs.de Czech Republic H [email protected] Germany, Austria, China Czech Republic, Greece, Denmark I Hungary,
[Show full text]
C:\Data\Ndaenjuvia\AP LTR 05-07-04
NDA 21-443 Package Insert ENJUVIA™ (synthetic conjugated estrogens, B) Tablets Rx only ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of “natural” estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. (See WARNINGS, Malignant neoplasms, Endometrial cancer.) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (See WARNINGS, Cardiovascular disorders.) The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical Studies). The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen alone therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.) Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar.
[Show full text]
The Structural Biology of Oestrogen Metabolism
Journal of Steroid Biochemistry & Molecular Biology 137 (2013) 27–49 Contents lists available at ScienceDirect Journal of Steroid Biochemistry and Molecular Biology jo urnal homepage: www.elsevier.com/locate/jsbmb Review The structural biology of oestrogen metabolism ∗ Mark P. Thomas, Barry V.L. Potter Department of Pharmacy & Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY, UK a r t i c l e i n f o a b s t r a c t Article history: Many enzymes catalyse reactions that have an oestrogen as a substrate and/or a product. The reac- Received 11 September 2012 tions catalysed include aromatisation, oxidation, reduction, sulfonation, desulfonation, hydroxylation Received in revised form and methoxylation. The enzymes that catalyse these reactions must all recognise and bind oestrogen but, 10 December 2012 despite this, they have diverse structures. This review looks at each of these enzymes in turn, describing Accepted 12 December 2012 the structure and discussing the mechanism of the catalysed reaction. Since oestrogen has a role in many disease states inhibition of the enzymes of oestrogen metabolism may have an impact on the state or Keywords: progression of the disease and inhibitors of these enzymes are brieﬂy discussed. Oestrogen This article is part of a Special Issue entitled ‘CSR 2013’. Protein structure © 2012 Elsevier Ltd. Open access under CC BY license. Reaction mechanism Aromatase Sulfatase Sulfotransferase 17␤-Hydroxysteroid dehydrogenase Contents 1. Introduction . 27 2. Methods . 29 3. Oestrogen sulfotransferase . 29 4. Steroid sulfatase. 31 5. 17␤-Hydroxysteroid dehydrogenases . 33 6. Aromatase (cytochrome P450 19A1, oestrogen synthase) . 36 7. Enzymes of steroid hydroxylation .
[Show full text]
THE FORMATION of ESTROGENS by LIVER TISSUE in VITRO By
THE FORMATION OF ESTROGENS BY LIVER TISSUE IN VITRO by David Richard Usher, B. Se. A thesis submitted to the faeulty of Graduate Studies and Research in partial fulfilment of the requirements for the degree of Master of Science. Department of Investigative Medicine, McGill University, Montreal. April 1961 ACKNOWLEDGMENTS The author wishes to thank the Banting Research Foundation for financial support1 and the Research Director1 Dr. R. Hobkirk1 for much-appreciated advice and help througbout all aspects of this problem. Acknowledgment is also extended to Dr. R.H. Common for donation of the avian liver and to Mr. J. Knowles for assistance in the preparation of the figures. TABLE OF CONTENTS SECTION PAGE 1- Estrogen Nomenclature 1 2- Introduction 4 3- H:l.storical Survey i) Earliest work 5 ii) Experimental hepatic posioning 6 iii) Splenic implantation techniques 7 iv) Vitamin and protein-deficiency effects 7 v) Enterohepatic circulation of estrogens 9 vi) Species differences 11 vii) Estrogen content in adult liver 11 viii) In vivo - in vitro deficiency studies 12 ix) Investigations of the enzyme systems 12 x) Estrogens and hepatic disease 13 xi) Sex difference 15 xii) Role or the retieulo- endothelial system 15 xiii) Early in vivo estrogen interconversion 16 xiv) Perfusion studies 17 xv) The effect of partial hepatectomy 17 xvi) Incubation with cu1tured liver ce11s 17 xvii) In vitro estradiol conversion to estrone 18 xviii) Review of bioassay procedures 18 xix) Chemica 1 assays 19 i SECTION PAGE 3- Historical Survey - cont'd. xx) Countercurrent
[Show full text]
The Selective Estrogen Enzyme Modulators in Breast Cancer: a Review
Biochimica et Biophysica Acta 1654 (2004) 123–143 www.bba-direct.com Review The selective estrogen enzyme modulators in breast cancer: a review Jorge R. Pasqualini* Hormones and Cancer Research Unit, Institut de Pue´riculture, 26 Boulevard Brune, 75014 Paris, France Received 21 January 2004; accepted 12 March 2004 Available online 15 April 2004 Abstract It is well established that increased exposure to estradiol (E2) is an important risk factor for the genesis and evolution of breast tumors, most of which (approximately 95–97%) in their early stage are estrogen-sensitive. However, two thirds of breast cancers occur during the postmenopausal period when the ovaries have ceased to be functional. Despite the low levels of circulating estrogens, the tissular concentrations of these hormones are significantly higher than those found in the plasma or in the area of the breast considered as normal tissue, suggesting a specific tumoral biosynthesis and accumulation of these hormones. Several factors could be implicated in this process, including higher uptake of steroids from plasma and local formation of the potent E2 by the breast cancer tissue itself. This information extends the concept of ‘intracrinology’ where a hormone can have its biological response in the same organ where it is produced. There is substantial information that mammary cancer tissue contains all the enzymes responsible for the local biosynthesis of E2 from circulating precursors. Two principal pathways are implicated in the last steps of E2 formation in breast cancer tissues: the ‘aromatase pathway’ which transforms androgens into estrogens, and the ‘sulfatase pathway’ which converts estrone sulfate (E1S) into E1 by the estrone-sulfatase.
[Show full text]
Adrenal Dehydroepiandrosterone and Human Mammary Cancer1
[CANCER RESEARCH 38. 4036-4040. November 1978] 0008-5472/78/0038-OOOOS02.00 Adrenal Dehydroepiandrosterone and Human Mammary Cancer1 John B. Adams,2 Lesley Archibald, and Christine Clarke School ot Biochemistry. University of New South Wales, Sydney. Australia Abstract tion to weight (13, 15). Calculations suggested that over one-half of the differences in breast cancer incidence be A hypothesis implicating adrenal dehydroepiandroster- tween regions in Holland and Japan can be attributed to one (DHEA) (sulfate) in the etiology of human breast cancer of the "adrenal" or "Western" type has been differences in body weight and height (15). As pointed out by de Waard, such a combination can be interpreted as a presented (Adams, J. B. Steroid Hormones and Human measure of body surface area (15). A recent hypothesis has Breast Cancer. An Hypothesis. Cancer, 40: 325-333, implicated adrenal DHEA3-DHEAS in the etiology of human 1977). High concentrations of DHEA sulfate in the blood breast cancer, particularly of the "Western" or "adrenal" provide a potentially high flux of the free steroid to type (2). It was demonstrated that the metabolism of these mammary tumors, due to the presence therein of a sulfa steroids by human breast carcinoma tissue was very similar tase. The free steroid, in turn, is metabolized by human to that by skin; one possibility for this similarity is the mammary tumors in vitro to 5-androstene-3/i,17/J-diol reputed derivation of the mammary gland from primitive (ADIOL) and 7-hydroxydehydroepiandrosterone. It has sweat glands. It is possible that DHEA-DHEAS, the exact now been found that ADIOL when administered s.c.
[Show full text]
Pharmacology of Estrogens and Progestogens: Influence of Different Routes of Administration
CLIMACTERIC 2005;8(Suppl 1):3–63 Pharmacology of estrogens and progestogens: influence of different routes of administration H. Kuhl Department of Obstetrics and Gynecology, J. W. Goethe University of Frankfurt, Germany Key words: ESTROGENS, PROGESTOGENS, PHARMACOKINETICS, PHARMACODYNAMICS, HORMONE REPLACEMENT THERAPY ABSTRACT This review comprises the pharmacokinetics and pharmacodynamics of natural and synthetic estrogens and progestogens used in contraception and therapy, with special consideration of hormone replacement therapy. The paper describes the mechanisms of action, the relation between structure and hormonal activity, differences in hormonal pattern and potency, peculiarities in the properties of certain steroids, tissue-specific effects, and the metabolism of the available estrogens and progestogens. The influence of the route of administration on pharmacokinetics, hormonal activity and metabolism is presented, and the effects of oral and transdermal treatment with estrogens on tissues, clinical and serum parameters are compared. The effects of oral, transdermal (patch and gel), intranasal, sublingual, buccal, vaginal, subcutaneous and intramuscular adminis- tration of estrogens, as well as of oral, vaginal, transdermal, intranasal, buccal, intramuscular and intrauterine application of progestogens are discussed. The various types of progestogens, their receptor interaction, hormonal pattern and the hormonal activity of certain metabolites are described in detail. The structural formulae, serum concentrations, binding affinities to steroid receptors and serum binding globulins, and the relative potencies of the available estrogens and progestins are presented. Differences in the tissue-specific effects of the various compounds and regimens and their potential implications with the risks and benefits of hormone replacement therapy are discussed. INTRODUCTION The aim of any hormonal treatment of postmen- tance of pharmacological knowledge for an opausal women is not to restore the physiological optimal use of hormone therapy.
[Show full text]
Other Data Relevant to an Evaluation of Carcinogenicity and Its Mechanisms
COMBINED ESTROGEN−PROTESTOGEN MENOPAUSAL THERAPY 263 4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms 4.1 Absorption, distribution, metabolism and excretion The distribution of progestogens is described in the monograph on Combined estro- gen–progestogen contraceptives. That of estrogens is described below. 4.1.1 Humans Little more has been discovered about the absorption and distribution of estrone, estradiol and estriol products and conjugated equine estrogens in humans since the previous evaluation (IARC, 1999). Greater progress has been made in the identification and characterization of the enzymes that are involved in estrogen metabolism and excre- tion. The various metabolites and the responsible enzymes, including genotypic varia- tions, are described below (see Figures 3 and 4). Sulfation and glucuronidation are the main metabolic reactions of estrogens in humans. (a) Metabolites (i) Estrogen sulfates Several members of the sulfotransferase (SULT) gene family can sulfate hydroxy- steroids, including estrogens. The importance of SULTs in estrogen conjugation is demons- trated by the observation that a major component of circulating estrogen is sulfated, i.e. estrone sulfate (reviewed by Pasqualini, 2004). In addition to the parent hormones, estrone and estradiol, SULTs can also conjugate their respective catechols and also methoxyestro- gens (Spink et al., 2000; Adjei & Weinshilboum, 2002). The resulting sulfated metabolites are more hydrophilic and can be excreted. In postmenopausal breast cancers, levels of estrone sulfate can reach 3.3 ± 1.9 pmol/g tissue, which is five to nine times higher than the corresponding plasma concentration (equating gram of tissue with millilitre of plasma) (Pasqualini et al., 1996). In contrast, levels of estrone sulfate in premenopausal breast tumours are two to four times lower than those in plasma.
[Show full text]
Cenestin™ (Synthetic Conjugated Estrogens, A) Tablets Physicians Package Insert
NDA 20-992 Cenestin™ (synthetic conjugated estrogens, A) Tablets Physicians Package Insert Cenestin™ (synthetic conjugated estrogens, A) Tablets ] only PRESCRIBING INFORMATION ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CARCINOMA. Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that natural estrogens are more or less hazardous than synthetic estrogens at equivalent estrogen doses. DESCRIPTION Synthetic conjugated estrogens, A tablets contain a blend of nine (9) synthetic estrogenic substances. The estrogenic substances are sodium estrone sulfate, sodium equilin sulfate, sodium 17α-dihydroequilin sulfate, sodium 17α-estradiol sulfate, sodium 17β-dihydroequilin sulfate, sodium 17α-dihydroequilenin sulfate, sodium 17β-dihydroequilenin sulfate, sodium equilenin sulfate and sodium 17β-estradiol sulfate. The structural formulae for these estrogens are: Page: 1 Date printed: Mar 23, 1999 NDA 20-992 Cenestin™ (synthetic conjugated estrogens, A) Tablets Physicians Package Insert O O NaO SO 3 C H NaO S NaO SO 18 21 5 3 C H NaO S 372.42 18 19 5 370.41 Sodium Estrone Sulfate Sodium Equilin Sulfate OH OH NaO SO NaO SO 3 C H NaO S 3 18 21 5 C18H21NaO5S 372.42 372.42 Sodium Dihydroequilin Sulfate 6RGLXPÃ 'LK\GURHTXLOLQÃ6XOIDWH OH OH NaO SO NaO SO 3 3 C H NaO S C18H23NaO5S 18 23 5 374.44 374.44 6RGLXPÃ (VWUDGLROÃ6XOIDWH 6RGLXPÃ (VWUDGLROÃ6XOIDWH O OH NaO3SO NaO3SO C18H17NaO5S C18H19NaO5S 368.39 370.41 Sodium Equilenin Sulfate 6RGLXPÃ 'LK\GURHTXLOHQLQÃ6XOIDWH OH NaO3SO C18H19NaO5S 370.41 6RGLXPÃ 'LK\GURHTXLOHQLQÃ6XOIDWH Tablets for oral administration, are available in 0.625 mg and 0.9 mg strengths of synthetic conjugated estrogens.
[Show full text]
Additional Menopause Learning Issues And
Drs DeRuiter, Braxton-Lloyd and Breese, Endocrine Module, Spring 2002 MENOPAUSE/CONTRACEPTION/DUB SECTIONS: “BASIC SCIENCE” LEARNING OBJECTIVES • Describe the structure and function of the female reproductive system • Describe how peptide hormones of the hypothalamus and pituitary regulate reproductive system structure and function • Describe how steroid hormones regulate reproductive system differentiation, structure and function • Describe the production of steroid hormones in the ovarian substructures and how steroid hormone production is regulated by hypothalamic and pituitary peptide hormones. Note the key biosynthetic steps and precursors, and how genetics, disease and drugs may influence biosynthetic processes. • Characterize variations in hypothalamic and pituitary hormone levels and steroid hormone levels during maturation, puberty, pregnancy, the climacteric phase and menopause. • Generally describe how genetic defects or reproductive tissue pathologies may influence contribute to menstrual disorders/menopause • Describe the biochemical events involved in estrogen receptor stimulation and expression of estrogenic activity. Describe the different estrogen receptor subtypes and their tissue localization. • Generally describe the modulatory roles of the estrogenic hormones in skin and skeletal tissue, cardiovascular pathology, CNS function, the gut and other estrogen- dependent tissues (breast) • Describe the causes, clinical presentation, laboratory assessment of various reproductive tract disorders. • Describe the consequences of estrogen deficiency on the organ systems of the body • Describe the relationship between reproductive tract disorders and common comorbid conditions that develop • Describe the various structural sub-classes of estrogenic hormone drugs and how structure influences pharmacologic activity, key pharmacokinetic properties and adverse reaction profiles. Describe the rationale for differences in properties based on structure. • Describe the different formulations for the various structural sub-classes of steroid hormone drugs.
[Show full text]
Dehydroepiandrosterone Sulfotransferase As a Possible Shunt for the Control of Steroid Metabolism in Human Mammary Carcinoma1
[CANCER RESEARCH 37, 278-284, January 1977] Dehydroepiandrosterone Sulfotransferase as a Possible Shunt for the Control of Steroid Metabolism in Human Mammary Carcinoma1 J_ B. Adams2 and D. P. Chandra2 ImperialCancerResearchFund,Lincoln's Inn Fields,London,England(J. B. A.), and the Schoolof Biochemistry,Universityof NewSouth Wales, Kensington,AustraliafJ. B. A., D. P. C.) SUMMARY noid moiety can occur with the sulfate group intact, but such pathways appear to be of minor significance (21). Human primary mammary tumors were examined to de Oao and Libby (15, 16) have demonstrated that the sulfur termine what factors were of importance in deciding relative ylation of steroids by human mammary carcinoma tissue is rates of sulfurylation of dehydroepiandrostenone and 17$- highly correlated with prognosis and response to hormone estradiol, such rates having been shown to correlate with ablative procedures such as adnenalectomy. In patients un the patient's prognosis and response to adrenalectomy (T. dengoing adnenalectomy for late-stage breast cancer, the L. Oao and P. A. Libby. Enzymic Synthesis of Steroid Sul failure of tumor preparations to sulfurylate steroid hon fate by Mammary Cancer and Its Clinical Implications. NatI. mones in vitro was related to a particularly grave prognosis Cancer Inst. Monographs, 34: 205-210, 1971). The sulfur and a complete lack of response to adrenalectomy. When ylation of dehydroepiandrosterone and 17f3-estradiol was DHEA3 and 17f3-estradiol were compared as substrates for studied in 41 tumors in vitro using tumor cytosol, adenosine tumor sulfotransferases, then if the ratio of DHEA sulfate tniphosphate, [35S]SO42, Mg2@,and added steroid. Six tu formation to 17f3-estnadiol sulfate formation was <1, this mors showed no sulfurylating ability, 9 sulfurylated dehy was also associated with a poor prognosis and response to droepiandrosterone at a rate greater than that for 17$- adrenalectomy.
[Show full text]
International 2017 2 Table of Contents
Deuterium Labelled Compounds International 2017 2 Table of Contents International Distributors 3 Corporate Overview 4 General Information 5 Quality Control 5 Custom Synthesis 5 Chemical Abstract Service Numbers 5 Handling Hazardous Compounds 5 Our Products are Not Intended for Use in Humans 6 Limited Warranty 6 Packaging Information 6 Alphabetical Listings 7 Stock Clearance 235 Products by Category 241 n-Alkanes 242 α-Amino Acids, N-Acyl α-Amino Acids, N-t-BOC Protected α-Amino Acids 242 and N-FMOC Protected α-Amino Acids Buffers and Reagents for NMR Studies 244 Detergents 244 Environmental Standards 245 Fatty Acids and Fatty Acid Esters 248 Flavours and Fragrances 249 Gases 252 Medical Research Products 253 Nucleic Acid Bases and Nucleosides 254 Pesticides and Pesticide Metabolites 255 Pharmaceutical Standards 256 Polyaromatic Hydrocarbons (PAHs), Alkyl-PAHs, Amino-PAHs, 259 Hydroxy-PAHs and Nitro-PAHs Polychlorinated Biphenyls (PCBs) 259 Spin Labels 260 Steroids 260 3 International Distributors C Beijng Zhenxiang H EQ Laboratories GmbH Australia K Technology Company Graf-von-Seyssel-Str. 10 Rm. 15A01, Changyin Bld. 86199 Augsburg Austria H No. 88, YongDingLu Rd. Germany Beijing 100039 Tel.: (49) 821 71058246 Belgium J China Fax: (49) 821 71058247 Tel.: (86) 10-58896805 [email protected] China C Fax: (86) 10-58896158 www.eqlabs.de Czech Republic H [email protected] Germany, Austria, China Czech Republic, Greece, Denmark I Hungary, Poland, Switzerland D Central Chemicals Co., Inc. Estonia I Ishida Bldg., 4-chome 2-17 I QMX Laboratories Limited Nihonbashi-hongokucho Bolford Street Finland I Chuo-ku, Tokyo 103-0021 Thaxted, Essex CM6 2PY Japan United Kingdom France G Tel.: (81) 03 3242 1541 Tel.: (44) 1371 831611 Fax: (81) 03 3246 2566 Fax: (44) 1371 831622 Germany H [email protected] [email protected] www.qmx.com Greece H www.centralchem.co.jp United Kingdom, Ireland, Japan Denmark, Estonia, Finland, Hungary H Latvia, Lithuania, Sweden E Chemical Research 2000 S.r.l.
[Show full text]